Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Miles

Executive Summary

Forms Biological Products unit and new Biotechnology Business unit headed by Ralph Galustian and George Scangos, PhD, respectively. Galustian will continue in his current role as president of the expanded Biological Products unit, which is part of the Miles Pharmaceutical Division based in West Haven, Conn., company announces Sept. 9. The unit will have global responsibility for manufacturing and creating international strategic marketing partnerships for plasma-derived products and biotechnologically derived products. The unit, which employs 1,700 people, has manufacturing sites in Clayton, N.C., Berkeley and Covina, Calif. and Spokane, Wash. and annual sales of about $500 mil. The new biotech business unit, with offices in Berkeley and West Haven, will bring together research institutes formerly spread throughout Miles and its German parent Bayer AG, and will be responsible for licensing R&D and production of all biotech products. The biotechnology unit employs 1,100 people. The reorganization becomes effective Oct. 1.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS023304

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel